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Editorial
Effects of the 2017 clinical practice guidelines on hypertension in children and adolescents:
A commentary
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The Fourth Report on the Diagnosis, Evaluation, and Treatment of
High Blood Pressure in Children and Adolescents (Fourth Report) was
published in 2004 [1]. Subsequent research on blood pressure (BP) in
children led to many reports on the increasing prevalence of abnormal BP
in children, and on factors associated with abnormal BP that contributed
to heightened risk for cardiovascular disease in early adulthood. Based on
an expanded body of knowledge, the American Academy of Pediatrics
sponsored an update of the pediatric BP guidelines. The Clinical Practice
Guideline for Screening and Management of High Blood Pressure in
Children and Adolescents (CPG) was published in 2017 [2], and provides
comprehensive clinical guidance for detection, diagnosis, and manage-
ment of abnormal BP in pediatric patients. The overall clinical approach
in evaluation and management of hypertension in children and adoles-
cents is similar to the previous Fourth Report. However, two key changes
in the new CPG are likely to confer a change in detection and prevalence
of abnormal BP and hypertension in youth. There is a consistent positive
association of overweigh and obesity status with higher BP in childhood
[3,4]. Removal of BP data on children with body mass index (BMI) >
85th percentile in the child normative BP database resulted in a some-
what lower BP level at each sex, age, and height adjusted BP percentile
[5]. These BP tables, based on normal weight children were used in the
2017 CPG. In the new tables, the BP levels at the 90th and 95th percentile,
used to deﬁne abnormal BP and hypertension, are 2–3 mmHg lower than
the systolic and diastolic BP levels in the Fourth Report.
The deﬁnition of hypertension in children <13 years of age remains
unchanged as systolic and/or diastolic BP  95th percentile. BP levels in
children previously termed “prehypertension” are now termed “elevated
BP” and for children<13 years of age. Elevated BP is deﬁned as BP 90th
percentile and<95th percentile. Normal BP for children<13 is <90th on
the sex, age, height adjusted BP tables. More signiﬁcant changes were
made in the deﬁnition of hypertension for adolescents 13 years of age.
For both males and females from age 13 and above a numerical value is
used to deﬁne BP status. Normal BP is < 120/80 mmHg. Elevated BP is
120–129/<80 mmHg. Hypertension stage 1 is 130–139/80–89 mmHg.
Hypertension stage 2 is >140/90 mmHg. These numerical values for
hypertension in adolescents are close to the 95th percentile, on the
revised BP tables, for most adolescents beginning at age 13 years, with
the exception of young very short adolescents. These deﬁnitions are also
identical to the new deﬁnitions of elevated BP and hypertension in the
recent update of the adult hypertension guidelines developed by the
American Heart Association and the American College of Cardiology [6].
The new CPG deﬁnitions of elevated BP and hypertension in adolescents
is expected to simplify recognition of abnormal BP in adolescents and
also expected to harmonize management in the progression from
adolescence to young adulthood.
Since publication of the CPG in 2017, several reports on the impact of
the new guideline have been published. These recent reports are based on
analysis of existing data previously obtained on child populations or
longitudinal cohorts with initial measurement of BP obtained in child-
hood. Sharma et al. [7] examined data on 15,647 generally healthy
children age 5–18 years from the National Health and Nutrition Exami-
nation Surveys (NHANES) in the period 1999 to 2014. Participants had
BP classiﬁcation based on the Fourth Report. Using the CPG to redeﬁne
BP status in these children resulted in an increase in prevalence of hy-
pertension from 11.8% (95% CI, 11.1%–13.0%), based on the Fourth
Report, to 14.2% (95% CI, 13.4–15.0) based on the CPG. Within the
entire cohort, 905 children (5.8%) had newly diagnosed hypertension or
an increase in BP status based on the new CPG. These children were
matched by sex, age, and height with controls having normal BP. Chil-
dren having BP status reclassiﬁed upward were more likely to be obese,
have adverse lipid proﬁles and increased hemoglobin A1c levels. These
results indicate that the upward classiﬁcation of BP status, based on the
CPG, in this cohort of otherwise healthy children, represent a high-risk
group of children whose cardiovascular risk may have been under-
estimated by the Fourth Report.
Another recent report examined the impact of the CPG in a cohort of
high-risk youth. Khoury et al. [8] examined application of the CPG on
hypertension and association with target organ damage (TOD) measures
in a cohort of 364 adolescents age 10–18 years with obesity and type 2
diabetes. TOD measurements included carotid artery intima-media
thickness, pulse wave velocity, left ventricular mass, and diastolic func-
tion. The prevalence of hypertension increased from 8% based on the
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Fourth Report to 13% based on the CPG. The two guidelines both showed
similar associations of BP with TOD. However, the new CPG demon-
strated improved sensitivity for TOD detection. As an example, the
portion of participants, classiﬁed as hypertensive, with abnormal left
ventricular mass increased from 20%, based on the Fourth Report, to
32% based on the CPG. These results indicate that the new CPG may
improve detection of cardiac injury markers in high-risk children.
In another study, Bell et al. [9] reanalyzed data from the Houston
Pediatric and Hypertension school screening program on 22,224 children
age 10–17 years. BP status in this cohort of school children had been
classiﬁed according to criteria in the Fourth Report. The authors reported
that with application of the new CPG criteria, the prevalence of elevated
BP, previously termed prehypertension, increased from 14.8% to 16.3%.
The prevalence of conﬁrmed hypertension, based on repeated measure-
ment, remained at 2%–4%. It was also noted that, based on the CPG,
shorter children <13 years and taller older children (>13 years) were
more likely to be up-classiﬁed in BP status.
The new CPG was compared to the Fourth Report on an even larger
cohort by Dong et al. [10] The BP status and related risk factors were
compared in 50,336 Chinese youth age 6–17 years. The prevalence of
high BP (both elevated BP and hypertension) was higher based on the
CPG at 16.7% of children<13 years and 7.9% of adolescents compared to
10.6% in children and 6.3% of adolescents based on the Fourth Report.
The prevalence estimates for high BP differed the greatest for boys,
children aged 11 years, those with high BMI, and those with tall stature.
In support of the CPG validity were strong associations between high BP
with BMI and other medical and behavioral factors. In a similar study, Al
Kibria et al. [11] compared the prevalence of hypertension according to
the Fourth Report and the CPG based on BP data of children age 8–17
years in two separate NHANES periods. Their analysis included 3633
children in NHANES 2005–2008 and 3471 children in NHANES
2013–2016. In the 2005–2008 NHANES period, the prevalence of hy-
pertension was 3.1% based on the Fourth Report classiﬁcation (95% CI,
2.3–4.3%). When BP status in this period was recalculated according to
the CPG, the prevalence of hypertension was 5.7% (95% CI, 4.6–7.1%).
Similarly, in the 2013–2016 NHANES period the prevalence of hyper-
tension based on the Fourth Report was 1.9% (95% CI, 1.4–2.6%). When
recalculated according to the CPG, the prevalence of hypertension was
3.5% (95% CI, 2.7–4.5%). Thus, the change in reference tables and
deﬁnition of hypertension for children 13 years results in the expected
increase in prevalence of childhood hypertension.
In another recent study, Kharbanda et al. [12] examined clinical BP
data of children and adolescents who were well-child patients, age 10–17
years, in a large primary care health system. Data were available in
electronic clinical records on individual patients over several years. The
investigators designed a prospective study and sought to determine the
rates of incident hypertension following persistent elevated BP based on
the new CPG compared to the Fourth Report. In this large cohort, 2025
youth (mean age 14.6 years) had elevated BP on repeated visits. During a
two-year follow-up period, 5.9% progressed to hypertension based on
CPG criteria compared to 1.1% based on Fourth Report criteria. Those
who progressed to hypertension tended to be older and obese. Overall,
the progression from elevated BP to hypertension was over 5-fold greater
based on the CPG compared to the Fourth Report. These results suggest
that the CPG may have greater capacity to identify youth with height-
ened risk for progression in BP status.
The Bogalusa Heart Study is a longitudinal cohort study that enrolled
3940 children. Child participants were then followed with repeated
measurements into mid-adulthood. Age at enrollment ranged from 3 to
18 years. Du et al. [13] conducted a study to evaluate cardiovascular
consequences of childhood hypertension based on the CPG deﬁnition of
hypertension compared to the Fourth Report deﬁnition of hypertension
in childhood. Themajor goal of this study was to compare performance of
these two guidelines in predicting adult hypertension, metabolic syn-
drome, and left ventricular hypertrophy (LVH). In childhood, hyperten-
sion was identiﬁed in 7% of the cohort by Fourth Report criteria
compared to 11% of the cohort according to the CPG. Both guidelines had
similar signiﬁcant associations of childhood BP with adult hypertension,
metabolic syndrome, and LVH. However, the portion of children iden-
tiﬁed as hypertensive in childhood who developed LVH in adulthood
increased from 12% identiﬁed by the Fourth Report to 19% of those
identiﬁed by the CPG. Thus, the new CPG guideline identiﬁed a group of
children with heightened risk for adverse cardiovascular outcomes, a risk
that was under-estimated by the Fourth Report guideline.
The above reports, based on existing data from large cohorts, compare
prevalence of abnormal BP, associated risk factors, and outcomes based
on the new CPG compared to the Fourth Report. The elimination of BP
data on overweight and obese children from the normative BP data tables
lowered the BP levels at the 90th and 95 percentile BP level; and it was
expected to increase the childhood prevalence of elevated BP and hy-
pertension somewhat. To date, the new CPG appears to provide greater
sensitivity in detection of youth with other risk factors associated with
abnormal BP. The new CPGmay also enable early recognition of youth at
greater risk for premature cardiovascular disease in early adulthood.
Additional study is needed on the effect of the change in deﬁnition of
abnormal BP for children 13 years of age, wherein a single number
deﬁnes hypertension in boys and girls and is equivalent to the deﬁnition
in older adults.
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